Food Effect Study Of AG-013736 In Healthy Volunteers
NCT00918632 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2009-08-04
Summary
The study is designed to evaluate the effect of food on typical blood levels obtained after oral dosing of AG-013736. Drug levels in blood will be compared after an overnight fast and a high-fat, high-calorie meal.
Conditions
- Healthy Volunteers
Interventions
- DRUG
-
AG-013736
A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> B -\> C. Each of these treatments will be separated by a 7 day washout period.
- DRUG
-
AG-013736
A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -\> C -\> B. Each of these treatments will be separated by a 7 day washout period.
- DRUG
-
AG-013736
A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> C -\> A. Each of these treatments will be separated by a 7 day washout period.
- DRUG
-
AG-013736
A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -\> A -\> C. Each of these treatments will be separated by a 7 day washout period.
- DRUG
-
AG-013736
A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> A -\> B. Each of these treatments will be separated by a 7 day washout period.
- DRUG
-
AG-013736
A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -\> B -\> A. Each of these treatments will be separated by a 7 day washout period.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2009-07-31
- Completion
- 2009-07-31
Countries
- Belgium
Study Locations
More Related Trials
-
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males
NCT04163783 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers
NCT00797342 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers
NCT01897142 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Potential Food Effects
NCT00791817 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
NCT03217604 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants
NCT04148209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
NCT06670170 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion
NCT01854996 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
NCT01626976 ·Status: COMPLETED ·Phase: PHASE1
-
Food Effect Study of AG120 in Healthy Subjects
NCT02579707 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.
NCT06532383 ·Status: COMPLETED ·Phase: PHASE1
-
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
NCT01646840 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants
NCT00886093 ·Status: COMPLETED ·Phase: PHASE1
-
Food Effect Study PF-04136309
NCT02598206 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
NCT01820936 ·Status: COMPLETED ·Phase: PHASE1
-
Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects
NCT02546635 ·Status: COMPLETED ·Phase: PHASE1
-
GLPG0259 Solid Formulation Bioavailability and Food Effect
NCT01024517 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants
NCT07127770 ·Status: COMPLETED ·Phase: PHASE1
-
First in Human Study for PF-06667272
NCT03126149 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers
NCT06122194 ·Status: COMPLETED ·Phase: PHASE1
-
Food Effect Study of AG-221 in Healthy Male Subjects
NCT02218346 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects
NCT04951765 ·Status: UNKNOWN ·Phase: PHASE1
-
Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679
NCT01393652 ·Status: COMPLETED ·Phase: PHASE1